about
sameAs
Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance -- a study of the OVCAD consortiumExpression profiling to predict the clinical behaviour of ovarian cancer fails independent evaluationPreoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) - a study of the TOC ConsortiumProteomic analysis of laser microdissected ovarian cancer tissue with SELDI-TOF MS.Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data.Proteomic biomarkers predicting lymph node involvement in serum of cervical cancer patients. Limitations of SELDI-TOF MS.A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortium.Endometrial safety of hormone replacement therapy: review of literature.Endometriosis and the development of malignant tumours of the pelvis. A review of literature.Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortiumThe management of borderline tumours of the ovary.Sentinel node in ovarian cancer: study protocol for a phase 1 study.Management of borderline ovarian neoplasms.Chemotherapy for recurrent cervical cancer.Predictive criteria for MRI-based evaluation of response both during and after radiotherapy for cervical cancer.Application of proteomics in ovarian cancer: which sample should be used?The role of diaphragmatic surgery during interval debulking after neoadjuvant chemotherapy: an analysis of 74 patients with advanced epithelial ovarian cancer.The utility of proteomics in gynecologic cancers.Overexpression of 17β-hydroxysteroid dehydrogenase type 1 increases the exposure of endometrial cancer to 17β-estradiol.The impact of enzastaurin (LY317615.HCl) on CA125 biosynthesis and shedding in ovarian cancer cells.The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer.Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD.Organoids of epithelial ovarian cancer as an emerging preclinical in vitro tool: a review
P50
Q28275893-B187D5A0-67EC-4194-B312-3F154E207134Q33315705-F5A2D4BF-6506-4BED-B798-23D62751CA3BQ33624809-4DB66F2B-7080-4791-87C3-2A0870789388Q33961876-37D1F38A-9F70-4F10-B0C3-650C5FF2EE67Q34135353-4DC93F7E-5C6B-4F80-8D28-DFB1243B1379Q34302950-C1DFFE53-74DB-4EC7-9F1D-2ECF926969FFQ34646749-ADABF900-AA52-4D25-9188-497DB89016C7Q34686445-528A68BB-A4DF-408E-AD15-DB378AFE79F2Q35780943-BB9EC785-591C-4682-950A-63A81CC00EA9Q36498614-E2385DE9-45A7-45AC-9BCB-CA08255BD54BQ36559230-261427C6-BB4C-4A6F-BE99-B1405F67E6D8Q36624373-6A1DA737-4554-451F-B881-E9C2E6050159Q36873072-0BA4D91E-B679-4FA8-BA20-89E5F19B8A17Q36931130-01EE0326-DD08-45D7-8F0A-314041D855DCQ37136709-93E56FC6-87EA-4734-9816-1F8DB1D0A067Q37610568-24F1861C-1EEF-4182-99BA-58EAC06F48AAQ37777949-B9FF91BA-699D-4F70-AEDE-4F803348544BQ37828490-6B61325E-C94C-47D6-AD11-613A0EA6D0D1Q39390875-F5A8EAF5-A5CE-478D-8D4E-5152663DC4CDQ39708067-25E5DD91-CFFF-4255-AAFA-AC59DA41F562Q40450021-D0F58C34-1E7A-4C5C-A4FE-439F986904E5Q42684807-38617887-81BF-426D-8B87-BCB0F6AC54C8Q91192808-3BE05955-4931-42B5-A36A-21C5902F1C77
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher ORCID ID = 0000-0002-1573-8716
@en
wetenschapper
@nl
研究者
@zh
name
Toon Van Gorp
@ast
Toon Van Gorp
@en
Toon Van Gorp
@es
Toon Van Gorp
@nl
Toon Van Gorp
@sl
type
label
Toon Van Gorp
@ast
Toon Van Gorp
@en
Toon Van Gorp
@es
Toon Van Gorp
@nl
Toon Van Gorp
@sl
prefLabel
Toon Van Gorp
@ast
Toon Van Gorp
@en
Toon Van Gorp
@es
Toon Van Gorp
@nl
Toon Van Gorp
@sl
P106
P1153
7801659525
P1695
P21
P214
1179147665856960670002
P31
P496
0000-0002-1573-8716
P569
2000-01-01T00:00:00Z
P735
P7859
viaf-1179147665856960670002